ArticlePloS one2025
Therapeutic patterns and outcomes in older patients (aged ≥ 65 years) with stage III inoperable non-small cell lung cancer (NSCLC): An investigational study from the SEER database.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An explainable attention-gated stacking ensemble model for predicting survival in non-small cell lung cancer: development and validation.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCurrently, optimal treatment regimens for older patients with stage III inoperable NSCLC remain unclear. The aim of this retrospective study was to investigate therapeutic patterns and survival outcomes in older patients with stage III inoperable NSCLC who received radiation therapy (RT) alone or combined with chemotherapy (CT).
methodsA retrospective analysis was conducted on 5740 patients aged ≥65 years with stage III inoperable NSCLC, using data from the Surveillance, Epidemiology, and End Results (SEER) registry (20182021). Patients treated with RT alone (n = 1077) were compared to those receiving RT + CT (n = 4663). Kaplan-Meier analysis and Log-rank tests were performed.
resultsThe estimated 3 years overall survival (OS) and cancer-specific survival (CSS) rates were 34.9% and 42.8%, respectively. Median OS and CSS were 21 and 28 months, respectively. Univariate analysis indicated that age, gender, T stage, pathological type and treatment option were independent prognosticators of OS and CSS. Multivariate analysis demonstrated that age, gender, T stage, N stage, and therapeutic strategy were correlated with OS, while gender, T stage, N stage and treatment option were independent prognostic factors for CSS. Subgroup analyses demonstrated that combining RT with CT improved OS in all patient subgroups, and improved CSS in all patients except those at stage N0.
conclusionIn patients aged ≥65 years with stage III inoperable NSCLC from the SEER database, treatment with RT plus CT provided longer OS and CSS compared to RT alone, except for patients with N0 stage disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.